Clinical Trial

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

Study acronym: PROTECT-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 8, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment. The aim is to evaluate the bone marrow protective effect of trilaciclib before docetaxel chemotherapy for locally advanced or metastatic NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-08; most recent amendment 2025-06-06.
Status change: Not Yet Recruiting → Recruiting 2025-06-06
Trial Details
NCT Number NCT06929936
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Non-Small Cell Lung Cancer, Myelosuppression
Enrollment 33 participants
Start Date 2025-05-09
Primary Completion 2026-05 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-08